Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.
企業コードRGNT
会社名Regentis Biomaterials Ltd
上場日Dec 04, 2025
最高経営責任者「CEO」Hazum (Eli)
従業員数- -
証券種類Ordinary Share
決算期末- -
本社所在地60, Medinat Hyahudim
都市HERZLIYA
証券取引所NASDAQ OMX – NASDAQ Basic Amex
国Israel
郵便番号4676652
電話番号97246265502
ウェブサイトhttps://www.regentis.co.il/
企業コードRGNT
上場日Dec 04, 2025
最高経営責任者「CEO」Hazum (Eli)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし